Advanced search
Publication Cover
Hematology Volume 29, 2024 - Issue 1
Submit an article Journal homepage
870
Views
0
CrossRef citations to date
0
Altmetric
Letter to the Editor

Combination therapy with venetoclax and azacitidine for the treatment of myelodysplastic syndromes with DDX41 mutations

Xin Wanga State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, People’s Republic of China;b Tianjin Institutes of Health Science, Tianjin, People’s Republic of ChinaView further author information
,
Zhijian Xiaoa State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, People’s Republic of China;b Tianjin Institutes of Health Science, Tianjin, People’s Republic of China;c MDS and MPN Centre, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, People’s Republic of China;d Hematologic Pathology Center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, People’s Republic of ChinaCorrespondence[email protected]
View further author information
,
Tiejun Qinc MDS and MPN Centre, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, People’s Republic of ChinaView further author information
,
Zefeng Xua State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, People’s Republic of China;c MDS and MPN Centre, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, People’s Republic of ChinaView further author information
,
Yujiao Jiad Hematologic Pathology Center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, People’s Republic of ChinaView further author information
,
Shiqiang Qua State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, People’s Republic of China;c MDS and MPN Centre, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, People’s Republic of ChinaView further author information
,
Bing Lia State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, People’s Republic of China;b Tianjin Institutes of Health Science, Tianjin, People’s Republic of China;c MDS and MPN Centre, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, People’s Republic of ChinaView further author information
,
Lijuan Panc MDS and MPN Centre, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, People’s Republic of ChinaView further author information
,
Qingyan Gaoc MDS and MPN Centre, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, People’s Republic of ChinaView further author information
,
Meng Jiaoc MDS and MPN Centre, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, People’s Republic of ChinaView further author information
&
Robert Peter Galee Department of Immunology and Inflammation, Haematology Research Centre, Imperial College London, London, UKView further author information
 show all
Article: 2338509 | Received 07 Feb 2024, Accepted 29 Mar 2024, Published online: 10 Apr 2024

References

  • Polprasert C, Schulze I, Sekeres MA, et al. Inherited and somatic defects in DDX41 in myeloid neoplasms. Cancer Cell. 2015;27(5):658–670. doi:10.1016/j.ccell.2015.03.017
  • Sebert M, Passet M, Raimbault A, et al. Germline DDX41 mutations define a significant entity within adult MDS/AML patients. Blood. 2019;134(17):1441–1444. doi:10.1182/blood.2019000909
  • Al-Kali A, Nanaa A, Viswanatha D, et al. Observation and treatment in DDX41-mutated acute myeloid leukemia and myelodysplastic syndrome. Blood Cancer Journal. 2023;13(1):49. doi:10.1038/s41408-023-00818-6
  • Gangat N, Karrar O, Iftikhar M, et al. Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: genotype signatures for response and survival among 301 consecutive patients. Am J Hematol. 2024;99(2):193–202. doi:10.1002/ajh.27138
  • Gangat N, Komrokji RS, Tefferi A. Venetoclax and hypomethylating agent therapy in myelodysplastic syndromes: Big picture perspective. Am J Hematol. 2023;98(2):225–228. doi:10.1002/ajh.26781
  • Dalle I A, Kantarjian H, Bannon SA, et al. Successful lenalidomide treatment in high risk myelodysplastic syndrome with germline DDX41 mutation. Am J Hematol. 2020;95(2):227–229. doi:10.1002/ajh.25610
  • Negoro E, Radivoyevitch T, Polprasert C, et al. Molecular predictors of response in patients with myeloid neoplasms treated with lenalidomide. Leukemia. 2016;30(12):2405–2409. doi:10.1038/leu.2016.228
  • Qu S, Li B, Qin T, et al. Molecular and clinical features of myeloid neoplasms with somatic DDX41 mutations. Br J Haematol. 2021;192(6):1006–1010. doi:10.1111/bjh.16668
  • Nyquist OE, Dalgaard J, Spetalen S, et al. Pathogenic DDX41 variants, possible response predictors to low-dose melphalan in hypo- and normocellular MDS and AML. Br J Haematol. 2024;204(2):724–729. doi:10.1111/bjh.19226
  • Bazinet A, Darbaniyan F, Jabbour E, et al. Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1-2 study. Lancet Haematol. 2022;9(10):e756–e765. doi:10.1016/S2352-3026(22)00216-2
  • Nanaa A, He R, Foran JM, et al. Venetoclax plus hypomethylating agents in DDX41-mutated acute myeloid leukaemia and myelodysplastic syndrome: Mayo Clinic series on 12 patients. Br J Haematol. 2024;204(1):171–176. doi:10.1111/bjh.19105
  • Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–2405. doi:10.1182/blood-2016-03-643544
  • Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120(12):2454–2465. doi:10.1182/blood-2012-03-420489
  • Bernard E, Tuechler H, Greenberg PL, et al. Molecular international prognostic scoring system for myelodysplastic syndromes. NEJM Evidence. 2022;1(7):1–14. doi:10.1056/EVIDoa2200008
  • Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006;108(2):419–425. doi:10.1182/blood-2005-10-4149
  • Wan Z, Han B. Clinical features of DDX41 mutation-related diseases: a systematic review with individual patient data. Ther Adv Hematol. 2021;12:20406207211032433. doi:10.1177/20406207211032433
  • Tiong IS, Stevenson WS, Wall M, et al. Favorable outcomes of DDX41-mutated myelodysplastic syndrome and low blast count acute myeloid leukemia treated with azacitidine +/- lenalidomide. EJHaem. 2023;4(4):1212–1215. doi:10.1002/jha2.767

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.